Compare CTRM & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRM | ABP |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 18.8M |
| IPO Year | N/A | N/A |
| Metric | CTRM | ABP |
|---|---|---|
| Price | $1.97 | $6.80 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.7K | ★ 207.2K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,859,415.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $1.84 | $4.55 |
| 52 Week High | $3.64 | $153.90 |
| Indicator | CTRM | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 88.76 |
| Support Level | $1.85 | $5.34 |
| Resistance Level | $1.99 | $7.02 |
| Average True Range (ATR) | 0.07 | 0.49 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 48.83 | 73.00 |
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.